title: EGFR mutation testing practice in advanced non-small cell lung cancer.
abstract: OBJECTIVE
  Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients.
  
  
  METHODS
  An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients.
  
  
  RESULTS
  24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79% of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60% of participants recommend waiting for EGFR test results prior to initiation of first-line therapy.
  
  
  CONCLUSIONS
  EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.
authors: Department of Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel, bar.jair@gmail.com.
authors: Jair
authors: J
authors: Bar
authors: Arnold
authors: A
authors: Cyjon
authors: Dov
authors: D
authors: Flex
authors: Hadas
authors: H
authors: Sorotsky
authors: Haim
authors: H
authors: Biran
authors: Julia
authors: J
authors: Dudnik
authors: Nili
authors: N
authors: Peylan-Ramu
authors: Nir
authors: N
authors: Peled
authors: Hovav
authors: H
authors: Nechushtan
authors: Maya
authors: M
authors: Gips
authors: Rivka
authors: R
authors: Katsnelson
authors: Shoshana Keren
authors: SK
authors: Rosenberg
authors: Ofer
authors: O
authors: Merimsky
authors: Amir
authors: A
authors: Onn
authors: Maya
authors: M
authors: Gottfried
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D004252:DNA Mutational Analysis / Q000706:statistics & numerical data / Q000639:trends*; D066246:ErbB Receptors / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D019538:Health Care Surveys; D006801:Humans; D020407:Internet; D007557:Israel; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009154:Mutation; D010641:Phenotype; D010818:Practice Patterns, Physicians' / Q000639:trends*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors